【Destiny Pharma-Product XF-73】New Asian (APSIC) guidelines for prevention of surgical site infections recommend decolonisation of Staphylococcus aureus in surgical patients to prevent surgical site infections

Partner News

17th December 2019– Destiny Pharma issued an announcement, which is summarized as follows: 

Destiny Pharma notes that new guidelines from the Asia Pacific Society for Infection Control (APSIC) for the prevention of surgical site infections have been published in the peer-reviewed journal, Antimicrobial Resistance and Infection Control. These guidelines underline the market potential of Destiny Pharma’s lead product XF-73 which is in Phase 2b clinical trials testing its ability to kill Staphylococcus aureus bacteria in the patient’s nose prior to surgery thereby reducing the potential for serious post-surgical bacterial infections including MRSA.

Neil Clark, Chief Executive Officer of Destiny Pharma, commented:

“This new Asian review strongly supports the potential for Destiny Pharma’s lead product, XF-73, to meet the guidelines’ clinical recommendation to prevent post-surgical infections by decolonising whilst mitigating the emergence of AMR. Previous independent publications in the US and from the World Health Organisation already support this approach. XF-73 nasal gel is currently in a Phase 2b clinical trial in the US and Europe and we look forward to reporting results in mid-2020. There is a significant commercial opportunity for XF-73, which is estimated to have potential peak annual product sales of $1 billion in the US alone.”

The APSIC guidelines also support Destiny Pharma’s strategic approach in China where it has a regional collaboration with China Medical Systems, a specialty pharmaceutical company focusing on the sale of prescription drugs and other medicinal products to all therapeutic departments in hospitals across the China region.

Original website Link: